MicroRNAs as biomarkers for ischemic heart disease by Van Aelst, Lucas & Heymans, Stephane
Van	  Aelst	  L	  et	  al.	  	  
	   1	  
MicroRNAs as biomarkers for ischemic heart disease 
 
Van Aelst; miR and CAD 
 
Lucas N.L. Van Aelst, MD1, 2; Stephane Heymans, MD PhD1, 3, 4 
 
1Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, Box 911, 
3000 Leuven, Belgium.  
2Department of Cardiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, 
Belgium.  
3Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), 
University Hospital Maastricht, 6229 HX Maastricht, the Netherlands. 
4Interuniversity Cardiology Institute Netherlands (ICIN), Royal Netherlands Academy of 
Sciences, Utrecht, the Netherlands. 
 
Word Count: max 6000 words (excluding references and figure legends); max 6 figures. 
 
Corresponding author: 
Stephane Heymans, MD PhD 
Cardiovascular Research Institute Maastricht, Maastricht University 
Department of Cardiology, University Hospital Maastricht 
Universiteitssingel 50, room 3214 
P. Debyelaan 25 
6202 AZ Maastricht 
The Netherlands 
Fax: +31 (0)433871055 
Phone: +31 (0)433882949 , +31 (0)433882950 
E-mail: s.heymans@maastrichtuniversity.nl 
Van	  Aelst	  L	  et	  al.	  	  
Abstract 
MicroRNAs (miRs) are short, non-coding RNAs that function as posttranscriptional 
inhibitors of mRNA translation to protein.  They are essential for normal development and 
homeostasis.  Dysregulated expression patterns both cause and result from disease states.  
Generally studied as intracellular mediators, miRs can be isolated from body fluids and 
exhibit remarkable stability to degradation.  These features, in combination with their tissue 
specificity, make miRs attractive candidates as blood-derived biomarkers for coronary artery 
disease (CAD), the most frequent cause of death worldwide.    
The use of miRs as biomarkers in both symptomatic and asymptomatic CAD and the 
influence of conventional cardiovascular risk factors and CAD treatment on their circulating 
levels is the topic of this review.  To conclude, it highlights the remaining hurdles to tackle 
before this promising application of miRs can enter into routine clinical practice. 
 
Key words: microRNA – coronary artery disease – biological markers – myocardial 
infarction – heart failure. 
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Introduction 
MicroRNAs (miRs) are single-stranded, phylogenetically conserved, non-coding RNA 
molecules of ~22 nucleotides which inhibit mRNA translation to protein by interacting with 
its 3’ untranslated region[1].  They are crucially involved in many aspects of cardiac 
development, homeostasis and pathobiology[2].  Although miRs function as endogenous 
intracellular regulators of mRNA translation, they can be detected in circulating blood or its 
components in a remarkably stable form and therefore should be considered disease 
biomarkers, for instance in cardiovascular diseases[3]. 
Ischemic heart disease virtually always results from coronary artery disease (CAD).  It is the 
most frequent cause of death worldwide and accounts for seven million deaths annually.  
Heart failure, silent ischemia, angina pectoris (AP) and myocardial infarction (MI) are its 
main clinical manifestations[4].  Acute coronary syndrome (ACS) is a collective noun for AP 
and MI, manifesting clinically as crushing chest pain with accompanying repolarization 
changes on the electrocardiogram (ECG).  In the acute care setting, differentiating ACS and 
non-cardiac causes of chest pain remains a diagnostic challenge[5].  However, a correct early 
diagnosis is associated with improved outcome[6], underscoring the need for a reliable 
biomarker for the early detection of cardiomyocyte death.  Current guidelines advocate the 
use of the MB fraction of creatine kinase (CK-MB) or cardiac troponins T and I (TnT and I) 
released in the circulation by damaged cardiomyocytes to diagnose MI[7] and stress the 
importance of serial measurements to ”rule in” or “rule out” MI, as Tn or CK-MB elevations 
might be delayed[8].  This low sensitivity during the first 6 hours (h) after the onset of chest 
pain is a major drawback of contemporary assays, partially resolved by the introduction of 
high sensitive (hs) Tn assays, with a sensitivity of 3 hours[8].   
In ischemic heart failure (HF), CAD hampers the heart to meet the metabolic demands of the 
body[9].  Typical symptoms suffice to make a diagnosis of HF, but identification of CAD as 
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its etiology requires additional invasive tests[10]. A reliable biomarker would obviate the 
need for these potentially harmful investigations.   
This report summarizes the current knowledge on the use of circulating miRs as diagnostic 
and prognostic biomarkers in asymptomatic and symptomatic CAD.  It also describes the 
effect of CAD risk factors and different medications typically initiated after ACS on 
circulating miR levels.  To conclude, we discuss their value in relation to existing biomarkers 
and indicate remaining gaps to bridge before their implementation in routine clinical practice 
(Table 1,2; Figure 1).   
 
MiR stability in blood and blood-derived products 
The existence of circulating miRs notwithstanding high plasma RNase activity suggests their 
shielding from enzymatic degradation in addition to their resistance to physical conditions 
inducing immediate degradation of free RNA (e.g. repeated freeze-thawing, prolonged 
exposure to room temperature)[3].  Accumulating evidence shows that lipid vesicles, 
lipoprotein complexes and proteins protect circulating miRs. 
In contrast with initial beliefs, lipid vesicles carry only a minority of circulating miRs[11].  
Apoptotic bodies are the largest of these lipid vesicles (up to 4 µm), shed when cells undergo 
apoptosis.  Microvesicles (100 nm – 1 µm) bud from the plasma membrane under 
physiological and pathological conditions as packages containing a set of biological signals 
modulating cellular behaviour at a distance[12].  Exosomes are small vesicles (50 – 90 nm), 
derived from the endosomal compartment and released when multivesicular bodies fuse with 
the plasma membrane[12,13].  Higher levels of distinct miRs in exosomes than in their donor 
cells suggest an active mechanism of miR loading into multivesicular bodies and 
exosomes[14,15].  Recently, also high-density lipoproteins (HDL) were implicated in 
shielding circulating miRs[16]; hereby, neutral sphingomyelinase regulated miR export to 
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HDL and scavenger receptor class B type I mediated miR delivery to recipient cells.  
However, the majority of circulating miRs are bound to RNA-binding proteins.  The exact 
release mechanism is unknown, but may be mere passive release upon disruption of the 
plasma membrane.  Argonaute 2 (Ago2), which acts intracellularly in concert with miRs to 
form an RNA-induced silencing complex, as well as nucleophosmin 1 (NPM1) have been 
implicated as protein carriers for circulating miRs[11,17,18]. 
The early release of cardiomyocyte-enriched miR-1, miR-133a/b and miR-208 in ACS 
suggests ‘leakage’ from necrotic cardiomyocytes[19,20], with the slow rise of miR-499 
attributable to slower release of its carrier protein.  However, in this regard, the repeated 
inability to detect other cardiomyocyte enriched miRs such as miR-24 and miR-30c in blood 
or its components upon cardiac ischemia is remarkable and suggests active degradation and 
release mechanisms such as apoptosis and resulting release of apoptotic bodies.  Furthermore, 
depletion of ATP with resultant increase in intracellular calcium concentration leads to 
augmented extrusion of exosomes by cardiomyocytes in vitro[21].  While activated or 
apoptotic endothelial cells release microvesicles respectively apoptotic bodies in the 
circulation[22-24], primary human fibroblasts primarily release non-vesicle associated miRs 
following serum deprivation in vitro.  This fragmentary combination of in vitro and in vivo 
observations on the biochemical composition and the timing of release of extracellular miRs 
only gives a rough and incomplete sketch of the exact proportion of vesicle-associated and 
non-vesicle-associated circulating miRs (and their respective subfractions) in various disease 
states and healthy individuals.  Additional research is essential to address these questions and 
obtain a detailed and comprehensive picture, which could permit the isolation of miRs 
specifically enriched in selected subfractions, certain cell types or at specific time points, thus 
creating more sensitive biomarker assays.  
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Cardiomyocyte enriched miRs 
MiR-1 and miR-133a represent the most abundantly expressed cardiac miRs and derive from 
two bicistronic miR clusters, miR-1-1/miR-133a-2 and miR-1-2/miR-133a-1[25].  The latter 
cluster lies in intron 12 of mindbomb E3 ubiquitin protein ligase 1 (MIB1), a protein 
involved in apoptosis.  MiR-1-1 and miR-1-2, as well as miR-133a-1 and miR-133a-2 are 
identical in humans[25,26].  MiR-133b, specifically expressed in skeletal muscle, differs 
from miR-133a in the 2 terminal nucleotides at the 3’ end[25].  MiR-1 and miR-133 are 
essential for skeletal and cardiac muscle cell proliferation and differentiation[27].  In adult 
hearts, they exhibit an anti-hypertrophic effect[28].   
Experimental MI in rodents[19,21,29,30] and in pigs[31] resulted in decreased expression of 
miR-1 and miR-133a in the infarcted area, and increased levels in whole blood or its 
components.  Accordingly, human autopsy samples of infarcted tissue demonstrated 
downregulation of miR-1 and miR-133a/b[32].  Multiple reports[19-21,29-31,33-40] 
described significantly higher circulating levels of miR-1 and miR-133a in ACS compared to 
healthy controls, using either serum or plasma, either early or late (up to 24h) after MI.  
Plasma miR-1 and miR-133a/b levels paralleled those of conventional and high-sensitive 
Tn[30,35].  Areas under the curve (AUC) in receiver operating characteristics (ROC) curves 
ranged between 0.57 and 0.98 for miR-1[20,31,40] and 0.86 and 0.9468 for miR-
133a[21,31,39].  Considerable overlap in miR-1 and miR-133a plasma levels in unstable 
angina (UA) and MI precluded their use for further subdivision of ACS[35].  Apart from 
serving as a biomarker for the diagnosis of ACS, circulating levels of miR-1 and miR-133a at 
3 days (d) post-MI negatively correlated with renal function[31].  More importantly, their 
levels also associated with long-term major adverse cardiac events (MACE) and surrogate 
endpoints (infarct size, cardiac function and QRS duration) following MI.  While miR-1 
levels associated with QRS duration[20], infarct size[20,41] and negatively correlated with 
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systolic and diastolic cardiac function, especially in first MI[42], miR-133a predicted survival 
at 6 months post-MI[35], infarct size, reperfusion injury and decreased myocardial salvage 
following primary coronary intervention[43]. 
MiR-208a/b derive from the introns of the cardiac specific α- and β-myosin heavy chains 
(MYH6 and MYH7) respectively and are involved in stress-dependent cardiac growth and 
gene expression (fetal gene program)[44].  MiR-208 expression significantly increased in 
infarcted cardiac tissue compared to healthy tissue[32].  The suitability of miR-208a 
specifically as a circulating biomarker in CAD is controversial considering the contradictory 
information gathered: some considered miR-208a a reliable biomarker for stable CAD and 
ACS[19,34-36,45], whereas others failed to detect miR-208a in a considerable proportion of 
ACS patients studied and ultimately stopped verifying it as a biomarker[46,47].  Nonetheless, 
ROC curve analysis reportedly demonstrated AUC values of 0.965 for miR-208a in positive 
studies; for miR-208b, these values ranged between 0.82 and 1[31,39,40,48].  Importantly, 
when limiting the analysis to plasma samples obtained within 4 h after the onset of chest pain, 
miR-208a was more sensitive than conventional cardiac TnI to diagnose MI.  MiR-208a’s 
binding to cytosolic proteins readily released following cardiomyocyte damage might 
account for its earlier appearance in plasma compared to Tn.  Comparable with miR-1 and 
miR-133a/b, miR-208b showed a large overlap between the different manifestations of ACS, 
hence making discrimination between UA and MI impossible with miR-208b[35,40].  In 
addition to providing diagnostic information, miR-208b also conveyed important prognostic 
information as it negatively correlated with ejection fraction (EF)[31,48], a composite of 
mortality or heart failure within 30 days of hospitalization[40] and all cause mortality at 6 
months[35]. 
MiR-499 is located in an intron of β-myosin heavy chain 7b (MYH7b) and plays a role in 
myosin gene regulation.  MiR-499 has its own promoter and alternative splicing can 
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uncouple miR-499 expression from MYH7b when coexpression is not required[49].  MiR-
499’s plasma levels consistently increased within 12-48 h after the onset of MI and its slower 
release kinetics caused its peak level to occur only 24h after coronary occlusion[30].  
Reported AUC values ranged between 0.822 and 1[19,31,35-37,39,45,48,50].  Large overlap 
between its circulating levels in the different presentations of ACS precluded the use of miR-
499 to pinpoint the exact ACS manifestation[35,40].  In geriatric patients, miR-499 allowed 
discrimination between non-ST elevation MI (NSTEMI) patients and acute HF patients[37].  
Circulating levels of miR-499 also related to clinical outcomes and prognosis apart from 
delayed cardiomyocyte loss diagnosis as there was a weak negative correlation between miR-
499 and EF in ST elevation MI (STEMI)[48]; moreover, miR-499 strongly associated with 
mortality or heart failure within 30 days of hospitalization[40]. 
 
Fibroblast enriched miRs 
The genomic localization of miR-21 overlaps with the protein-coding gene transmembrane 
protein 49 (TMEM49 or vacuole membrane protein 1, VMP1), implicated in intracellular 
vacuole formation and cell death[51].  However, miR-21 has its own promoter, and its 
transcription occurs independently of TMEM49[52].  MiR-21 is well characterized as an 
important regulator of cardiac fibrosis[25,53].  In eldery NSTEMI patients (mean age > 80 
years), miR-21 increased within 4-9h after the onset of symptoms[37], whereas in stable 
CAD[33] and type 2 diabetes mellitus (DM)[54], it decreased compared to healthy controls.  
However, in a large population study, miR-15, miR-29b, miR-126, miR-223 and miR-28-3p 
showed a stronger association with incident DM type 2 and miR-21 was abandoned to 
classify and predict DM[33,54]. 
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Endothelial cell enriched miRs 
MiR-126 is encoded by intron 7 of the EGF-like domain 7 gene, which acts as a 
chemoattractant and inhibitor of smooth muscle cell migration[55].  MiR-126 is specifically 
expressed in endothelial cells and is the most abundant endothelial miR[56].  It is selectively 
enriched in microvesicles released by apoptotic endothelial cells and upregulates endothelial 
CXCL12 and CXCR4 signaling in neighbouring cells, linking increased miR-126 expression 
to improved atherosclerotic plaque stability by enhanced progenitor cell influx, increased 
smooth muscle cell content and decreased macrophage content[24]. 
Impaired miR-126 packaging in microparticles and apoptotic bodies upon exposure to high 
glucose caused lower plasma miR-126 levels in type 2 DM compared to matched 
controls[54].  In line with this, patients with stable CAD had lower serum and plasma miR-
126 compared to healthy controls[33].  However, two groups of patients diagnosed either 
with non-cardiac chest pain or stable CAD following coronary angiography had comparable 
circulating miR-126 levels; thus rendering its use as a biomarker for stable CAD 
controversial in a clinically more relevant situation[36,57].  In addition, higher aortic EDTA 
plasma levels and an increased transcoronary gradient of miR-126 in Tn positive acute 
coronary syndromes (ACS) suggested miR-126 consumption during transcoronary passage 
through the culprit vessel[36].  Intriguingly, one study measured decreased venous miR-126 
plasma levels in MI patients compared to healthy controls up to one week following the 
event; corresponding AUC values to diagnose MI ranged between 0.83 and 0.88[38].  In the 
general population, plasma miR-126 positively associated with incident MI[58].  In ischemic 
HF, plasma miR-126 levels negatively correlated with New York Heart association (NYHA) 
score and brain natriuretic peptide (BNP) levels but increased upon clinical improvement[59].  
However, the studied NYHA class III and IV patients had more diabetes and advanced 
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atherosclerosis and these confounding variables could also explain the observed 
downregulation of miR-126. 
The miR-17-92 cluster (miR-17, 18a, 19a, 20a, 19b-1 and 92a-1) is located in an intergenic 
region and expression occurs from a single transcription unit forming a polycistron[25].  
Plasma and serum miR-17 and miR-92a were significantly reduced in stable CAD compared 
to healthy controls[33], though analogous to miR-126, plasma levels were similar in patients 
with non-cardiac chest pain and stable CAD undergoing coronary angiography[36].  The 
latter study also demonstrated a significant increase in arterial plasma levels of miR-92a in 
Tn positive ACS patients compared to patients with stable CAD.  
 
Inflammatory cell enriched miRs 
MiR-155 maps within the B cell integration cluster (BIC) located on chromosome 21 and is 
to date one of the most extensively studied miRs with firmly established roles in neoplastic 
diseases, haematopoiesis, inflammation and both adaptive and innate immunity.  Moreover, 
miR-155 regulates the renin-angiotensin system by its interaction with the 3’ UTR of 
angiotensin 1 receptor (AT1R)[60,61].  Serum and EDTA-plasma levels of miR-155 were 
significantly lower in CAD patients compared to healthy volunteers[33].  However, miR-155 
could not reliably differentiate between stable CAD and ACS in patients undergoing 
coronary angiography and its levels did not correlate with circulating hs Tn[36].  
Interestingly, elevated serum miR-155 levels at the time of hospital discharge following MI 
predicted cardiac death within one year[62]. 
The miR-223 locus lies on the X chromosome and its transcription occurs independently of 
any known genes.  It fine-tunes the generation and function of granulocytes[63].  The 
suitability of miR-223 as a robust biomarker seems dubious as one study showed a mild 
though significant decrease in its plasma levels in STEMI patients compared to patients with 
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atypical chest pain[45], whereas another trial discovered a trend towards an increase in its 
plasma levels in ACS compared to patients with stable CAD or no evidence of CAD[36].  In 
both studies, miR-223 did not correlate with circulating Tn levels. 
 
Smooth muscle cell enriched miRs 
MiR-143 and miR-145 are contained in a bicistronic cluster on the (non-coding) miR-143 
host gene.  They drive the differentiation from multipotent stem cells to smooth muscle cells 
and oscillations in their cellular concentrations alter the proliferative potential of vascular 
smooth muscle cells[64].  In acute STEMI, circulating miR-145 isolated from blood cells 
drawn 3.0 ± 2.3 h after the onset of symptoms, significantly increased and correlated with 
infarct size estimated by hs TnT release[65].  Patients with stable CAD had significantly 
reduced serum and EDTA plasma levels of miR-145[33].   
 
Non-cardiac specific miRs 
In addition to the aforementioned miRs examined in multiple trials, there are still others, 
typically non-cardiac or skeletal muscle specific, associated with CAD, ACS or post-MI 
prognosis validated in a few experiments at most.  In general, three methodological 
approaches account for these observed differences.  First, these peculiar miRs were 
specifically chosen.  Second, rather than a priori selection of miRs (typically cardiac specific), 
few investigators started with a derivation cohort whose derived miRs they subsequently 
tested in a validation cohort.  Third, whereas most research focused on cell-free miRs, only 
few studies used whole blood or peripheral blood mononuclear cells (PBMC) to detect miRs 
with biomarker potential.   
Plasma miR-328, miR-30a and miR-195 significantly increased, while let-7b significantly 
decreased following MI compared to healthy subjects; furthermore, miR-328 peaked before 
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cardiac TnI[34,66].  Plasma miR-423-5p significantly increased in geriatric acute HF and 
NSTEMI patients[37]. Interestingly, elderly acute HF patients had the highest miR-423-5p 
levels, which corroborated an earlier report[67], yet contested by others[68,69].  In whole 
blood, miR-1291 and miR-663b showed the highest sensitivity and specificity for the 
discrimination of STEMI patients from controls (AUC 0.91 and 0.94 respectively).  However, 
addition of other significantly dysregulated miRs created a 7 and 20 miR signature which 
predicted STEMI with even higher precision than any single miR (AUC 0.99) and 
outperformed hs TnT at early (< 4 h) time points[65,70].  Decreased plasma miR-150 levels 
at discharge predicted left ventricular (LV) remodeling following STEMI.  Importantly, miR-
150 outperformed N terminal-pro-brain natriuretic peptide (NT-pro-BNP) to predict LV 
remodeling (AUC 0.74 and 0.60)[71].  Serum miR-380* at discharge associated with cardiac 
death at 1 year following MI[62].  Whole blood miR-30c correlated with infarct size 
estimated by hs TnT[65]. 
In PBMC from CAD patients, the expression of miR-135a was 5-fold increased, while miR-
147 was 4-fold decreased compared to healthy volunteers.  Furthermore, miR-134, miR-198 
and miR-370 differentiated UA from stable AP[72].  
 
Treatment effects and influence of conventional cardiovascular risk factors  
Few studies rigorously assessed the correlation between circulating miRs and conventional 
cardiovascular risk factors (age, gender, renal function, previous MI, hypertension and 
smoking status) in patients presenting with ACS[20,33,35,43,45]; furthermore, many 
restricted the correlation analysis to cardiomyocyte enriched miRs.  Small sized studies 
typically ruled out any influence of the aforementioned clinical variables on the studied 
miR(s).  These conclusions appeared valid for the study itself, however, the opposing 
conclusions from moderate sized studies seemed more reliably applicable to the general 
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population: significant univariate relations existed between miR-1 and renal function as well 
as smoking status; miR-133a correlated with age, previous MI and smoking; miR-499 
associated with male gender.  In multiple regression analyses, miR-1 independently 
associated with renal function, miR-133a with age and renal function, miR-208b with age and 
smoking and miR-499 with male gender[35].  Whereas total cholesterol, HDL and LDL 
moderately correlated with plasma and serum miR-155 in CAD, both age and renal function 
showed an inverse correlation.  Furthermore, females CAD patients had significantly higher 
levels of circulating miR-155 compared to males. 
Vasculoprotective therapies with statins, aspirin and inhibitors of the renin-angiotensin 
system (angiotensin converting enzyme inhibitors and angiotensin receptor blockers) 
significantly decreased plasma levels of endothelial cell (miR-126, miR-17-92 cluster), 
smooth muscle cell (miR-145) and inflammatory cell (miR-155) enriched miRs in a 
combined analysis of healthy volunteers and CAD patients.  When restricting the analysis to 
CAD patients, only endothelial cell enriched miRs and statin therapy remained independently 
associated.  Similarly, miR-133a decreased upon statin and aspirin treatment in a combined 
cohort of healthy volunteers and CAD patients, but the association disappeared when 
selectively analyzing CAD patients[33].  Highly controversial as other studies could only 
partially confirm these results[36,57], these findings nonetheless remain intriguing as they 
suggest that miRs could help in clinical practice to reliably gauge pleiotropic and protective 
effects of statins and other drugs routinely started following ACS and in CAD. 
Whole blood gene expression profiling before and after a 10 weeks cardiac rehabilitation 
exercise program demonstrated increased circulating miR-92a and miR-92b levels and 
decreased levels of their targets involved in mitochondrial function and oxidative 
phosphorylation, indicative of a ‘healthier’ profile upon completion of the program[73]. 
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Ready for prime time? 
The assessment of the clinical potential of a novel cardiovascular biomarker is structured 
around three fundamental questions[74].  First, accurate measurements must be possible at a 
reasonable cost and with short turnaround times; second, the biomarker must add new and/or 
more accurate information; third, the biomarker must help the clinician in the management of 
patients. 
Current quantification of miRs relies on polymerase chain reaction (PCR).  PCR is readily 
available, easy to perform, sensitive and specific; however, results vary from day to day in 
contrast to ELISAs used for serum protein biomarkers, which are well established and have 
little day-to-day variation[75].  Furthermore, the complete process of miR isolation, reverse 
transcription and finally PCR itself takes several hours, thus new, preferably bedside tests 
need to be developed to make miRs more appealing for routine clinical use.  In addition, the 
way of reporting circulating miR levels needs standardization.  Nowadays, results are 
frequently reported as a fold change compared to an endogenous, supposedly unchanging 
miR, a spiked-in synthetic miR or the circulating level of the studied miR in a control group.  
However, analogous to other laboratory tests, reporting the absolute number of molecules per 
volume unit is feasible and more straightforward[29].   
The experimental use of miRs as biomarkers in ACS coincided with the introduction of hs Tn 
assays in routine clinical practice, which allow definite MI diagnosis within three hours after 
presentation.  In the small to medium-sized clinical studies performed to date, the diagnostic 
potential of selected cardiac enriched miRs using contemporary quantification tools 
approaches the sensitivity and specificity of hs Tn assays.  However, these already executed 
trials used a plethora of biological materials (serum, plasma, whole blood, blood cells), and 
RNA isolation and quantitation tools.  Large, multicenter, prospective trials with uniform 
sample handling and miR quantition are now mandatory in the first place to value the real 
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potential of miRs in comparison to contemporary Tn assays.  Furthermore, aiming at 
substituting already clinically embedded hs Tn assays with miR based assays to diagnose 
ACS seems an unrealistic goal.  Rather, developing miR based assays to make a diagnosis of 
ACS in selected clinical situations in which Tn based assays have a lower specificity seems a 
more reasonable goal, e.g. for the diagnosis of myocardial damage in patients with end stage 
renal disease, sepsis, myocarditis, or heart failure.  Moreover, rather than focusing on one 
single or a set of miRs just to make a diagnosis of cardiomyocyte loss, profiling a set of miRs 
using current technologies should help to obtain additional invaluable information to tailor 
available treatments to each individual patient, as some miRs can inform about the duration 
of coronary occlusion, others give an indication of infarct size, still others about reperfusion 
injury and myocardial salvage.  Apart from thus providing detailed information on the infarct 
burden itself, miRs might also help to identify those patients at higher risk for complications 
of ACS such as renal impairment, arrhythmogenesis and heart failure, justifying intensified in 
hospital monitoring and/or post-discharge follow-up.  In the case of heart failure, distinct miR 
profiles might provide enough diagnostic information to diagnose its etiology, avoiding 
invasive procedures with their inherent risks.  Thus, rather than aiming to replace the more 
familiar Tn based assays, we should embrace miRs and their potential to provide 
complementary information on infarct and reperfusion characteristics, as well as short term 
and long term repercussions on distant organs and the whole organism. 
 
… not yet 
In conclusion, miRs are promising biomarkers for symptomatic and asymptomatic CAD 
providing direct understanding of detrimental pathophysiological processes in which they are 
themselves crucially involved.  As such, they provide valuable diagnostic and prognostic 
information about CAD and ACS.  Importantly, rather than aiming at substituting available 
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biomarkers for ACS (Tn) and HF (NT-pro-BNP), the community should focus on 
supplementing these with miR profiles to obtain complementary information.     
However, several challenges still lie ahead before their routine clinical application.  First, 
essential knowledge on their biochemical composition in blood is still lacking.  In addition, 
some technical issues need to be resolved to make miRs more attractive for routine clinical 
use of which shorter turnaround times, increased sensitivity of assays and adequate 
standardization of extraction and quantitation are the most urgent ones.  Most importantly, 
large, multicenter and prospective trials need to be initiated to assess the real diagnostic value 
of miRs.  
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 Figure Legends 
Figure 1. Circulating miRs as biomarkers in stable CAD, DM type 2 (top) and ACS 
(bottom).  Overview of miRs whose circulating levels were repeatedly shown to be altered in 
the indicated clinical conditions.  
 
Van	  Aelst	  L	  et	  al.	  
	   25	  
Figure Legends 
Figure 1. Circulating miRs as biomarkers in stable CAD, DM type 2 (top) and ACS 
(bottom).  Overview of miRs whose circulating levels were repeatedly shown to be altered in 
the indicated clinical conditions.  
St
ab
le 
CA
D 
&
 
Di
ab
et
es
Ac
ut
e C
or
on
ar
y 
Sy
nd
ro
m
e
Endothelial Cell Cardiomyocyte Fibroblast Smooth Muscle Cell
↑ miR-1
↑ miR-133a/b
↑ miR-208a/b
↑ miR-499
↑ miR-21
↓ miR-21 ↓ miR-126
↓ miR-17, miR92a
↑ miR-126
↓ miR-145
↑ miR-145
Van	  Aelst	  L	  et	  al.	  
	   27	  
Table 1: Studies with miRs as biomarkers for asymptomatic CAD and DM type 2. 
Disease  Specimen Sample size Main findings Ref. 
Stable CAD EDTA-Plasma (derivation cohort); 
serum (validation cohort) 
Derivation cohort:  
n(CAD) = 36 ; n(Ctrl) = 17. 
Derivation cohort: 
↓ miR-126, miR-17, miR-92a, miR-199a, miR-155, miR-145. 
↑ miR-133a. 
[33] 
Validation cohort:  
n(CAD) = 31 ; n(Ctrl) = 14. 
Validation cohort: 
↓ miR-126, miR-17, miR-92a, miR-155, miR-145. 
 
Type 2 DM Plasma n(DM) = 80 ; n(Ctrl) = 80. ↓ miR-24, miR-21, miR-20b, miR-15a, miR-126, miR-191, miR-197, 
miR-223, miR-320, miR-486 
[54] 
Bruneck cohort, n = 822  ↓ miR-126 in DM   
Stable CAD Plasma n(CAD) = 31 ; n(Ctrl) = 36  Failure to repeat observation of dysregulated miR-126 in CAD. 
MiR-126 inversely associated with LDL cholesterol in CAD patients. 
MiR-126 positively associated with LDL cholesterol in Ctrl patients.  
[57] 
Type 2 DM Plasma Bruneck cohort, n = 820 MiR-126 associated with incident MI. 
MiR-223 and miR-197 inversely associated with future MI. 
[58] 
(Un)stable 
CAD 
Whole blood n(SAP ) = 25 [stable CAD] ; 
n(UAP) = 25 [unstable CAD] ; 
n(Ctrl) = 20 
↑ miR-135a, ↓ miR-147 in CAD vs Ctrl. 
MiR-142-3p, miR-223, miR-150, miR-21, miR-16 and let-7a not 
significantly different between CAD and Ctrl. 
[72] 
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↑ miR-134, miR-370, ↓ miR-198 in UAP vs SAP 
Stable CAD Whole blood n(CAD) = 12 ; n(Ctrl) = 12  
 
↑ miR-140-3p, miR-182 
365 differentially expressed genes: 175 genes upregulated; 190 genes 
down-regulated.  
[73] 
  10 CABG patients before and 
after cardiac rehabilitation 
↑ miR-92a, miR-92b 
645 differentially expressed genes: 196 genes upregulated; 449 genes 
downregulated.  
 
 
Abbreviations: CABG: coronary artery bypass grafting; CAD: coronary artery disease; Ctrl: Controls; DM: diabetes mellitus; MI: myocardial 
infarction; miR: microRNA; Ref.: Reference; SAP: stable angina pectoris; UAP: unstable angina pectoris. 
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Table 2: Studies with miRs as biomarkers for ACS. 
Disease  Specimen Sample size Main findings Secondary findings Ref. 
MI (< 12h) Plasma n(MI) = 33 ;  
n(non-MI chest pain) = 33 ;  
n(Ctrl) = 30 
↑ miR-1, miR-133a, miR-499, 
miR-208a 
AUC(miR-208a) = 0.965 ; AUC(miR-499) = 0.822 ; 
AUC(miR-1) = 0.847 ; AUC(miR-133a) = 0.867 
AUC(TnT) = 0.987 
[19] 
MI Citrate-Plasma n(AMI) = 93 ; n(Ctrl) = 66. ↑ miR-1 AUC(miR-1): 0.7740 
MiR-1 levels correlated with QRS duration. 
[20] 
ACS  
(< 24h; 7/29 
undetermined) 
Serum n(ACS) = 29 ; n(non-ACS) = 42  ↑ miR-1 , miR-133a MiR-208a detectable in a few patients only. 
↑ MiR-1 and miR-133a in UA and apical ballooning. 
AUC (miR-1) = 0.777 ; AUC(miR-133a) = 0.932 
[21] 
MI (< 24h) Serum n(MI) = 31 ; n(Ctrl) = 20. ↑ miR-1 Positive correlation with CK-MB levels (r=0.68). [29] 
STEMI (< 14h) EDTA-Plasma 
 
n(STEMI) = 33 (25 + 8) ;  
n(Ctrl) = 17. 
↑ miR-1, miR-133a, miR-
133b, miR-499-5p. 
↓ miR-122, miR-375. 
↑ miR-208a could not be reproduced. 
MiR-1, miR-133a/b peak occurred before TnI. 
Slower kinetics of miR-499: peak after 24h. 
[30] 
STEMI (< 24h) Plasma n(STEMI) = 25 ; n(Ctrl) = 11 ↑ miR-1, miR-133a, miR-
208b, miR-499-5p 
miR-1 and miR-133 detectable in urine. 
AUC in STEMI < 12 h; AUC(miR-208b) = 1 ; 
AUC(miR-1) = 0.98 ; AUC(miR-133a) = 0.86 ; 
AUC(miR-499-5p) = 0.99 
[31] 
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MiR-1 (r2 = 0.27) and miR-133a (r2 = 0.17) levels at 
day 3 negatively correlated with GFR. 
Peak values of miR-208b negatively correlated with 
EF (r2 = 0.32) and positively correlated with peak 
levels of TnT (r2 = 0.25) at day 1.   
MI (< 24h) EDTA-Plasma 
and whole 
blood 
n (AMI) = 51 ;  
n(Ctrl) = 28 
↑ miR-133 and miR-328 in 
plasma and whole blood. 
Plasma: 
AUC(miR-133) = 0.890 ; AUC(miR-328) = 0.810 
 
Whole blood: 
AUC(miR-133) = 0.702 ; AUC(miR-328) = 0.872 
 
No association with arrhythmias detected. 
[34] 
ACS Plasma n(UA) = 117 ;  
n(NSTEMI) = 131 ;  
n(STEMI) = 196. 
↑ miR-1, miR-133a, miR-208b 
in (N)STEMI compared with 
UA. 
 
miR-133b, miR-208a, miR-499 not elevated in MI 
compared to UA. 
Considerable overlap between the three diagnostic 
groups. 
miR-133a and miR-208b associated with risk of death. 
[35] 
ACS and CAD EDTA-Plasma n(ACS) = 19 ; n(CAD) = 31 ; 
n(no CAD) = 7 
↑ miR-499, miR-133a, miR-
208a in ACS vs. CAD.   
Transcoronary decrease of miR-126 and miR-92a 
suggestive of consumption by the culprit artery. 
[36] 
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↑ in miR-92a, miR-126. Transcoronary increase of miR-133a and miR-499. 
NSTEMI in the 
eldery (< 9h) 
EDTA-Plasma n(NSTEMI) = 92 ;  
n(acute CHF) = 81 ;  
n(Ctrl) = 99 
↑ miR-133a, miR-423-5p, 
miR-21, miR-499-5p in 
NSTEMI and acute CHF vs 
Ctrl. 
↑ miR-21 and miR-499-5p in 
NSTEMI vs acute CHF. 
↑ miR-423-5p in acute CHF vs 
NSTEMI. 
AUC(miR-499-5p) = 1 in NSTEMI 
AUC(cTnT) = 1 in NSTEMI 
AUC(miR-499-5p) = 0.88 in acute CHF 
AUC(cTnT) = 0.78 in acute CHF 
AUC(miR-499-5p) = 0.88 in NSTEMI vs acute CHF 
AUC(cTnT) = 0.93 in NSTEMI vs CHF 
AUC(miR-499-5p) = 0.86 ; AUC(cTnT) = 0.68 ; 
AUC(hs-TnT) = 0.70 to distinguish NSTEMI from 
acute CHF with mild elevation of cTnT (< 0.10 
ng/mL). 
[37] 
MI  
(+/- 4h + time 
series) 
Plasma n(MI) = 17 ; n(Ctrl) = 25. ↑ miR-1 up to one week after 
MI. 
↓ miR-126 up to one week 
after MI. 
AUC(miR-1) = 0.90 – 0.96 
AUC(miR-126) = 0.83 – 0.88 
[38] 
MI (< 12h) EDTA-Plasma n(MI) = 67 ; n(Ctrl) = 32. ↑ miR-1, miR-133a, miR-
208b, miR-499 
No significant differences in the levels of these four 
miRs between STEMI and NSTEMI. 
AUC(miR-1) = 0.8265 ; AUC(miR-133a) = 0.9468 ; 
AUC(miR-208b) = 0.8899 ; AUC(miR-499) = 0.8841 ; 
[39] 
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AUC(cTnT) = 0.9820. 
None of four miRs tested superior to cTnT for MI 
diagnosis. 
MI (< 1 week) EDTA-Plasma n(STEMI) = 173 ; n(NSTEMI) = 
146 ; n(Ctrl) = 88. 
↑ miR-208b, miR-499-5p in 
(N)STEMI. 
↑ miR-1 in STEMI 
Diagnostic accuracy for MI: AUC(miR-1) = 0.57 , 
AUC(miR-208b) = 0.82 , AUC(miR-499-5p) = 0.79 ; 
AUC(hs TnT) = 0.95. 
MiR-208b (OR: 1.79) and miR-499-5p (OR: 1.70) 
associated with compound of death < 30 days, heart 
failure, EF < 40% or cardiogenic shock. 
Prognostic accuracy: AUC(miR-208b) = 0.64 , 
AUC(miR-499-5p) = 0.64 ; AUC(hs TnT) = 0.66. 
Strong correlation with hs TnT of miR-208b (r = 0.65) 
and miR-499-5p (r = 0.62). 
Weak negative correlation with LVEF of miR-1 (r = -
0.11), miR-208b (r = -0.16) and miR-499-5p (r = -
0.16). 
[40] 
MI Plasma n(MI) = 49 miR-1 negatively correlates 
with systolic and diastolic 
function 
MiR-1 negatively correlates with EF (r = -0.7605), FS 
(r = -0.5120) and E/A (r = -0.6862). 
Result driven by first MI subgroup. 
[42] 
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STEMI (<12h) Serum n(STEMI) = 216 ↑ miR-133a associated with 
decreased myocardial salvage, 
larger infarcts, more 
pronounced reperfusion injury. 
If miR-133a ≥ median more likely to have anterior 
infarction, diabetes, higher Killip class, longer time 
from symptom onset to reperfusion, higher peak CK 
levels, higher frequency of incomplete ST-segment 
resolution < 70% after reperfusion, more reduced EF. 
Death, reinfarction, new CHF within 6 months after 
infarction higher in miR-133a ≥ group. 
[43] 
MI (< 12h) Citrate-Plasma n(AMI) = 32 ; n(Ctrl) = 36. ↑ miR-133a, miR-208b, miR-
499 
↓ miR-223. 
AUC(miR-208b): 0.944 
AUC(miR-499): 0.918 
Correlation with TnT and CK levels of miR-499 (r = 
0.69 resp. r = 0.41) and miR-208b. 
[45] 
MI (< 12h) Citrate-Plasma n(STEMI) = 397 ;  
n(NSTEMI) = 113 ; n(Ctrl) = 87 
↑ miR-208b, miR-499 in both 
STEMI and NSTEMI vs. 
Control. 
Higher miR-208b and miR-499 levels in STEMI vs 
NSTEMI patients.. 
AUC(miR-499) = 0.97 ; AUC(miR-208b) = 0.90 ; 
AUC(hs-cTnT) = 0.97  
[48] 
ACS (< 48h) EDTA-Plasma n(AMI) = 9 ; n(UA) = 5 ;  
n(CHF) = 15 ; n(Ctrl) = 10. 
↑ miR-499 MiR-499 correlated with CK-MB. [50] 
Ischemic heart 
disease , CHF 
EDTA-Plasma n(ischemia) = 33 ; n(Ctrl) = 17. ↓ miR-126 in CHF Failure to repeat observation of increased miR-423-5p 
in CHF[67]. 
[59] 
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MI Serum Derivation cohort:  
n(cardiac death⏐MI) = 7 ;  
n(event free⏐MI) = 7. 
11 miRs differently expressed. ↑ miR-134, miR-155, miR-18a, miR-192, miR-380* 
↓ miR-125-5p, miR-212, miR-331-3p, miR-223*, 
miR-190b, miR-93*. 
[62] 
  Validation cohort: 
n(cardiac death⏐MI) = 19 ;  
n(event free⏐MI) = 21. 
2 miRs differently expressed. ↑ miR-308*, miR-155 in cardiac death group.  
MI Whole blood n(MI) = 20 ; n(Ctrl) = 20. ↑ miR-663b, miR-1291 and 
119 other miRs. 
Creation of miR signature to 
predict MI. 
Creation of miR signature consisting of 20 miRs to  
predict MI (specificity 96%, sensitivity 90%, and 
accuracy 93%). 
AUC(miR-663b) = 0.94 ; AUC(miR-1291) = 0.91. 
MiR-30c and miR-145 correlate with infarct 
sizesestimated by TnT release. 
[65] 
MI (+/- 4h + 
time series) 
Plasma n((MI) = 18 ; n(Ctrl) = 30. ↑ miR-30a 4-12 h after MI;  
↑ miR-195 8-12h after MI. 
↓ let-7b up to one week after 
MI. 
AUC(miR-30a) = 0.87 – 0.89 
AUC(miR-195) = 0.88 – 0.89 
AUC(let-7b) = 0.85 – 0.89 
AUC(miR-30a + miR-195 + let-7b) = 0.92 – 0.93  
[66] 
MI Whole blood n(MI) = 18 ; n(Ctrl) = 21. ↑ miR-181c* 
↓ miR-1915, miR-339-3p 
Creation of miR signature to 
Creation of miR signature consisting of 7 miRs to  
predict MI; highest discriminative power at 
presentation (0h) and 2h after presentation, with 
[70] 
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predict MI. AUC(0h) = 0.89 ; AUC(2h) = 0.92. 
MI Plasma n(STEMI) = 60 Identification of 10 miRs 
predicted to regulate LV 
remodeling. 
miR-27a, miR-133a, miR-625, miR-296-3p, miR-31, 
miR-23a, miR-204, miR-19a, miR-101, miR-150. 
[71] 
n(STEMI) = 30 ↓ miR-150 predicts LV 
remodeling 
AUC(miR-150) = 0.74 
AUC(NT-pro-BNP) = 0.60 
AUC(miR-150 + NT-pro-BNP) = 0.77 
MiR-150 reclassified 54% of patients misclassified by 
NT-pro-BNP and 59% of patients misclassified by 
multi-parameter clinical model. 
 
 
Abbreviations: ACS: acute coronary syndrome; AUC: area under the curve; CAD: coronary artery disease; CHF: congestive heart 
failure; CK: creatine kinase; Ctrl: Controls; DM: diabetes mellitus; EF: ejection fraction; FS: fractional shortening ; GFR: glomerular 
filtration rate; h: hours ; hs: high sensitive ; MI: myocardial infarction; miR: microRNA; NSTEMI: non-ST elevation myocardial 
infarction; NT-pro-BNP: N-terminal fragment of pro-brain natriuretic peptide; OR: Odds Ratio ; Ref.: Reference; STEMI: ST elevation 
myocardial infarction; Tn: Troponin; UA: unstable angina. 	  
